NEU001

NEU001is an innovative new drug developed by NeuCenBiomed, and NeOncTechnologies, Inc. in the United States for the treatment of nasopharyngeal carcinoma.

 

NEU001has two major features:

• Novel dosage form: The special vaporization technology platform allows the medicine to be concentrated at the location of the nasopharyngeal tumor by inhalation, and thus reducing side effects.

• New Chemical Entity  Innovative small molecule compounds that effectively enhance the therapeutic effect.

 

Other features of NEU001 include:

• Fulfills Unmet medical/market needs

• First in class

• Fast tract status

• Orphan Drug

 

NEU001 is expected to move into US FDA clinical trial review (IND) in the Q3 of 2022, and Phase 1 clinical trials is expected to be conducted in Taiwan.